{
  "report_rows": [
    {
      "kpi": "Adj. Diluted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$6.45 vs. cons $6.18",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health MLR (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~89.4% vs. cons ~89.9%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$48.6B vs. cons $48.82B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$27.25-$27.50 vs. cons ~$26.86",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Health MLR (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "reaffirm ~90.0-90.2% vs. cons ~90.2%",
      "confidence": "HIGH"
    },
    {
      "kpi": "CMS Sanctions (qualitative)",
      "prediction": "UNCHANGED",
      "answer": "confirm compliance steps completed; no new accrual [call: UNCHANGED / POSITIVE]",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2027 EPS growth commentary",
      "prediction": "UNCHANGED",
      "answer": "reaffirm >=12% growth; baseline rises with FY26 raise [call: UNCHANGED to BETTER]",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH - driven by estimate revisions on raised FY guide and higher 2027 baseline; CMS resolution removes tail risk and supports multiple expansion",
  "day5_confidence": "MEDIUM"
}